If you’re like most people, you probably assume that eye drops are Medicine. And while they are intended to be a treatment for various ailments, there are some that should not be taken without consulting a doctor first. Among these is Restasis, an over-the-counter steroid eye drop. Recently, Restasis has come under fire for allegedly causing long-term side effects, including vision loss and perforated eardrums. While Restasis is intended as a treatment for dry eyes, many users have reported experiencing side effects such as blurred vision and difficulty hearing. If you are considering using Restasis, it’s important to discuss the risks with your doctor first.
What is Restasis?
Restasis is a new prescription steroid eye drop that was approved by the FDA in March 2017. It is intended to be used for the treatment of dry eyes caused by various conditions, including age, inflammation, and other causes. Restasis is available as a single-use eyedrop, and is meant to be applied just once daily to the front surface of each eye.
Restasis works by reducing inflammation and restoring eyelid function. Initial studies suggest that it may be more effective than current treatments in treating dry eyes caused by various conditions. In addition, Restasis appears to be well-tolerated and has few side effects.
Side Effects of Restasis
Restasis is a steroid eye drop that is used to treat dry eyes. Side effects of restasis can include increased water retention, mood changes, and vision problems. If you are using restasis, be sure to talk to your doctor about any side effects you experience.
How Does Restasis Work?
Restasis is a medication that is used to treat eye pain and other symptoms of dry eye syndrome. It works by reducing the amount of tears that are produced in the eyes. This can improve the visibility and quality of vision. Restasis is available as a generic medication and is not expensive. It can be taken with or without food.
How Much Does Restasis Cost?
Restasis is a medication that is used to improve the symptoms of dry eye syndrome. It is available as a generic medication or under various brand names. The cost of restasis varies depending on the pharmacy you visit, but it typically costs around $40 per bottle.
Who is Eligible for Treatment With Restasis?
Restasis (dexamethasone ophthalmic solution) is a steroid eye drop that is used to treat glaucoma, a condition that results in increased pressure in the eye. Restasis is usually prescribed to people who have been diagnosed with open-angle glaucoma or high intraocular pressure (IOP). Although Restasis is approved for use by people of all ages, it is especially recommended for those over 55 years old and those who have experienced a decrease in vision due to glaucoma.
People who are eligible for treatment with Restasis should first be evaluated by their doctor to determine if they meet the qualifications for the medication. People who are considered candidates for Treatment with Restasis should also have an IOP below 20 mm Hg and an Open Angle Glaucoma diagnosis. A person’s age, sex, race, and other medical conditions cannot be used as factors in determining eligibility for treatment with Restasis.
Once a person has been determined to be eligible for Treatment with Restasis, their doctor will prescribe the appropriate dosage of the medication. The dosage of Restasis will be based on the patient’s age, sex, weight, IOP, and other medical conditions. After being prescribed a dosage of Restasis, patients will need to take the medication as prescribed every day. Patients should also monitor their IOP closely while taking this medication because it can cause optic nerve damage at high levels of IOP.
Restasis is an opioid eye drop that has been linked to several cases of serious side effects, including respiratory depression and even death. If you are considering using this product, be sure to speak with your doctor first to ensure that it is the best choice for you. And if you experience any adverse effects after taking Restasis, please report them to the FDA so that they can take action.